| Metric | Value ($ M) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 4.0K | 1.2% | 3.0% |
| Total Income | 4.0K | 1.2% | 3.0% |
| Expenditure | 3.3K | 3.6% | 3.5% |
| PBT | 598.00 | 11.0% | 1.7% |
| Net Profit | 456.00 | 3.8% | 8.6% |
| OPM | 17.67% | 1.95pp | 0.35pp |
| NPM | 11.53% | 0.60pp | 0.59pp |
| EPS | 0.24 | 4.0% | 9.1% |
Kenvue Reports Q2 2026 Results with 3.0% Net Sales Growth
06 Aug 2026 · 6 Aug, 4:22 pm
Summary
Kenvue Inc. reported its second quarter 2026 financial results, marking the third consecutive quarter of net and organic sales growth. Net sales increased by 3.0% to $3,955 million, with organic sales up 1.6%, driven by favorable value realization and volume growth across segments. Diluted EPS rose 9% to $0.24, and adjusted diluted EPS increased 7% to $0.31. The company highlighted strong performance in its Skin Health and Beauty segment and received FDA approval for Tylenol® with Naproxen. Due to the pending transaction with Kimberly-Clark, Kenvue will not be providing forward-looking guidance.
Key Highlights
- 1
Kenvue delivered its third consecutive quarter of net and organic sales growth, with net sales increasing 3.0% and organic sales increasing 1.6% in the second quarter of 2026.
- 2
Diluted Earnings Per Share (EPS) increased 9% to $0.24, and Adjusted Diluted EPS increased 7% to $0.31 compared to the prior year period.
- 3
Gross profit margin for the second quarter was 58.2%, and adjusted gross profit margin was 60.2%.
- 4
Operating income margin was 17.7%, with adjusted operating income margin at 22.1% for the second quarter.
- 5
Net sales in the Skin Health and Beauty segment increased 5.1% year-over-year, driven by organic sales growth of 3.7%.
- 6
Fiscal six months ended June 28, 2026, saw net cash flows from operating activities of $1.2 billion, an increase from $1.0 billion in the prior year period, leading to a Free cash flow of $1.0 billion.
- 7
Kenvue received FDA approval for Tylenol® with Naproxen, the first over-the-counter fixed-dose combination of acetaminophen and naproxen sodium.
Management Comments
Kirk Perry
We delivered our third consecutive quarter of net and organic sales growth, with broad-based gains across every segment and region. We also continued to drive operational efficiencies and increase strategic investment to fuel sustained momentum. Amidst a dynamic consumer and macro environment, our first-half 2026 results met or exceeded our expectations across key metrics, underscoring the strength and resilience of our people, brands, and new strategic plans. Our transformation is firmly on track. We remain focused on disciplined execution and continued business improvement while we work toward completing our value-creating combination with Kimberly-Clark in the fourth quarter of this year.
Informational and educational content only. Not investment advice.